Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992;284(2):71-6.
doi: 10.1007/BF00373372.

Psoriatic skin reveals the in vivo presence of an epidermal IL-1 inhibitor

Affiliations
Free article

Psoriatic skin reveals the in vivo presence of an epidermal IL-1 inhibitor

N I Kim et al. Arch Dermatol Res. 1992.
Free article

Abstract

Production of inhibitor(s) of IL-1 activity can be induced in keratinocytes by exposure to UVB. We describe in this study the characterization of an endogenous constitutively expressed IL-1 inhibitor which is present in extracts of human psoriatic epidermal keratome biopsies. Size-fractionated extracts of normal human epidermis did not reveal IL-1 inhibitory factor(s) activity in normal epidermis. Psoriatic epidermal extracts, however, contained virtually no IL-1 bioactivity and inhibited the activity of recombinant human IL-1 beta. This IL-1 inhibitor has a molecular weight of approximately 30 kDa and a pI of 5.3, as revealed by fast protein liquid chromatography size fractionation and chromatofocusing of psoriatic epidermal extracts. IL-1 inhibitory activity was not blocked by neutralizing anti-TGF beta monoclonal antibody. It did not have any inhibitory effect upon normal cellular proliferation but could block the IL-1 induction of IL-2 production by LBRM.33 cells as late as 4 h after exposure of LBRM.33 cells to IL-1. Thus, in vivo human psoriatic epidermis expresses an IL-1 inhibitor that specifically inhibits IL-1 activity but which appears distinct from previously described UV-induced epidermal IL-1 inhibitory activity or TGF beta.

PubMed Disclaimer

References

    1. Br J Dermatol. 1989 Jan;120(1):1-8 - PubMed
    1. J Invest Dermatol. 1986 Jun;86(6):643-8 - PubMed
    1. Arch Dermatol. 1990 Mar;126(3):351-5 - PubMed
    1. J Immunol. 1985 Jun;134(6):3882-6 - PubMed
    1. J Immunol. 1986 Apr 1;136(7):2348-57 - PubMed

Publication types